NCT00291447 is a Phase 1 clinical trial of ch806 in Neoplasms, sponsored by Ludwig Institute for Cancer Research.

Who is sponsoring NCT00291447?

NCT00291447 is sponsored by Ludwig Institute for Cancer Research.

What drugs are being tested in NCT00291447?

Interventions in NCT00291447: ch806.

Is NCT00291447 still recruiting?

NCT00291447 is currently completed. Last updated 3 October 2022.

Are results published for NCT00291447?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2022-10-03 · How we verify

NCT00291447

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase 1 Single Dose Escalation Trial of ch806 in Patients With Advanced Tumours Expressing the 806 Antigen

Completed Phase 1 Results posted Last updated 3 October 2022

What this trial tests

Phase 1 trial testing ch806 in Neoplasms in 8 participants. Completed in 10 August 2006.

Timeline

1 May 2005

Primary endpoint
16 February 2006

10 August 2006

Quick facts

Lead sponsor	Ludwig Institute for Cancer Research
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	8
Start date	1 May 2005
Primary completion	16 February 2006
Estimated completion	10 August 2006
Sites	1 location across Australia

Drugs / interventions tested

ch806 — full drug profile →

Conditions studied

Neoplasms — all drugs for Neoplasms →

Sponsor

Ludwig Institute for Cancer Research

Who can join

18 and older, any sex, with Neoplasms. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Number of Patients With Adverse Events
Time frame: 30 days
All AEs occurring during the study were documented on the respective case report form (CRF) pages. Events, which occurred after signed informed consent, but before first administration of study drug, were documented on the Pre-existing Signs and Symptom page. Thereafter, they were documented on the Adverse Event page. Toxicity was graded in accordance with the National Cancer Institute (NCI) Comm

Sponsor's own description

The purpose of this clinical trial is to describe the toxicity, biodistribution, pharmacokinetics and tumour uptake of a single infusion of ch806 (tagged with a trace amount of radioactive 111-Indium: 111In-ch806) in patients with advanced tumours expressing the 806 antigen.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

EGFR, the Lazarus target for precision oncology in glioblastoma.
Lin B, Ziebro J, Smithberger E, Skinner KR, et al · · 2022 · cited 34× · PMID 36125064 · DOI 10.1093/neuonc/noac204
Radiometals in Imaging and Therapy: Highlighting Two Decades of Research.
Sharma S, Pandey MK. · · 2023 · cited 13× · PMID 37895931 · DOI 10.3390/ph16101460
Dysregulation of post-translational modifications in glioma: advances in pathological mechanisms and clinical targeting strategies.
Wu J, Liu H, Li X, Huang H, et al · · 2026 · PMID 41652637 · DOI 10.1186/s12967-026-07743-9

Verify or expand the search:

Other recruiting trials for Neoplasms

Currently open trials in the same condition.

NCT07438782 — First Time in Human (FTIH) Study to Investigate the Safety and Preliminary Activity of GSK5533524 Alone or in Combinatio · Phase 1 · recruiting
NCT07382817 — Phase 1 Study of JV-394 Autologous Anti-CD94 CAR T for r/r CD94+ T/NK Cell Neoplasms · Phase 1 · recruiting
NCT07277270 — A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tum · Phase 1 · recruiting
NCT07257640 — IL-5 CAR-T Cell Therapy for Refractory/Relapsed Eosinophilic Leukemia · Phase 1 · recruiting
NCT07213609 — A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer · Phase 1, PHASE2 · recruiting

Other Ludwig Institute for Cancer Research trials

Trials by the same sponsor.

NCT03164772 — Phase 1/2 Study of Combination Immunotherapy and Messenger Ribonucleic Acid (mRNA) Vaccine in Subjects With NSCLC · Phase 1, PHASE2 · completed
NCT02963831 — A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies · Phase 1, PHASE2 · completed
NCT02898116 — Phase 1/2 Study of Ensartinib and Durvalumab, in ALK-rearranged Non-small Cell Lung Cancer · Phase 1, PHASE2 · completed
NCT02643303 — A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers · Phase 1, PHASE2 · completed
NCT02716805 — Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell Transplant · Phase 1 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00291447 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ludwig Institute for Cancer Research
Last refreshed: 3 October 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00291447.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing